SCHEMBL5897487

SCHEMBL5897487

Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1NC(=O)c1ccc2ncccc2c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.81
BRAF P15056 5/20 0.73
MAPK14 Q16539 11/20 0.69
KDM4E B2RXH2 2/20 0.69
ALDH1A1 P00352 2/20 0.69
MAPT P10636 2/20 0.69
HPGD P15428 2/20 0.69
RAF1 P04049 1/20 0.69
TP53 P04637 1/20 0.69
CYP1A2 P05177 1/20 0.69
CYP3A4 P08684 1/20 0.69
CYP2C9 P11712 1/20 0.69
ALOX15 P16050 1/20 0.69
MAPK11 Q15759 1/20 0.69
HSD17B10 Q99714 1/20 0.69
TDP1 Q9NUW8 1/20 0.69
HDAC6 Q9UBN7 1/20 0.69
HSF1 Q00613 1/20 0.67
SMO Q99835 2/20 0.65
NPC1 O15118 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2978412 0.93 CSF1R (0.70) CSF1RBRAFMAPK14KDM4EALDH1A1
SCHEMBL7853417 0.91 CSF1R (0.68) CSF1RBRAFMAPK14KDM4EALDH1A1
SCHEMBL5007830 0.90 MAPK14 (0.72) CSF1RBRAFMAPK14KDM4EALDH1A1
SCHEMBL6979265 0.89 BRAF (0.77) CSF1RBRAFMAPK14KDM4EALDH1A1
SCHEMBL5897251 0.89 BRAF (0.76) CSF1RBRAFMAPK14KDM4EALDH1A1
SCHEMBL7611676 0.86 RAB9A (0.61) CSF1RBRAFALDH1A1MAPTALOX15
SCHEMBL6975716 0.85 BRAF (0.72) CSF1RBRAFMAPK14KDM4EALDH1A1
SCHEMBL5897048 0.85 BRAF (0.71) CSF1RBRAFHSF1NPC1RAB9A
SCHEMBL5897754 0.84 BRAF (1.00) CSF1RBRAFMAPK14KDM4EMAPT
SCHEMBL5897233 0.84 MAPK14 (0.61) CSF1RBRAFMAPK14KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7060700-B2 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2006-06-13 US disclosed
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB 2003-06-05 US disclosed
US-6432949-B1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2002-08-13 US disclosed
EP-1102750-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007991-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines IL6, IL6ST, IL2 CSF1R 273/4885BRAF 1764/4885MAPK14 2563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.